Noah S Webb (Noah Webb)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 10

Top Topics

Cross Sectional

Emergency Department

Acute Lymphoblastic Leukemia

Allogeneic Hematopoietic Stem Cell Transplantation

Top Venues

Journal of comparative effectiveness research

International journal of chronic obstructive pulmonary disease

American journal of epidemiology

This page only lists publications with an associated author ORCID identifier.

Publications

Kristin Kahle-Wrobleski, Bonnie Khanh Ha Bui, Jennifer Friderici, Kristin J Moore, Maureen Carlyle, Noah S Webb, Carolyn K Martin, Wilson D Pace, John M Westfall
An Exploratory Study of Physician Decision-Making When Treating Uncontrolled COPD. International journal of chronic obstructive pulmonary disease 19 (2024)
L Hannah Gould, Rebecca Fee, John White, Noah S Webb, Maureen Carlyle, Laura Dick, Ye Tan, Valery Walker, Frederick J Angulo, Jennifer C Moïsi, James H Stark, Sarah J Pugh
Risk factors for Lyme disease among residents of rural, suburban, and urban areas in the United States: A Case-Control Study. American journal of epidemiology (2024)
Kristin Kahle-Wrobleski, Bonnie Khanh Ha Bui, Jennifer Friderici, Kristin J Moore, Maureen Carlyle, Noah S Webb, Carolyn K Martin, Wilson D Pace, John M Westfall
An Exploratory Study of Physician Decision-Making When Treating Uncontrolled COPD. International journal of chronic obstructive pulmonary disease 19 (2024)
T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research 13 (2) (2023)
T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research 13 (2) (2023)
T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research (2023)
T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research 13 (2) (2023)
T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research 13 (2) (2023)
T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research (2023)
T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research 13 (2) (2023)